<DOC>
	<DOCNO>NCT00324025</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group , multicenter efficacy safety trial evaluate Mycograb® . Subjects randomize receive either Mycograb® ( dose 1 mg/kg ) placebo first week induction therapy ( amphotericin B plus 5-flucytosine ) via central line peripheral venous line twice daily 7 consecutive day . The total duration study approximately 24 month .</brief_summary>
	<brief_title>Efficacy Safety Mycograb Adjunctive Therapy Cryptococcal Meningitis Patients With AIDS</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , parallel-group clinical trial design evaluate Mycograb® versus placebo adjunctive therapy antifungal induction therapy ( amphotericin B plus 5-flucytosine ) subject acute cryptococcal meningitis associate AIDS . After pre-study screening baseline assessment meet inclusion criterion , Day 1 subject randomize 1 2 treatment arm : Amphotericin B ( conventional 0.7 mg/kg , i.v . daily ) plus 5-flucytosine ( 100 mg/kg orally daily , divide QID ) , placebo . Amphotericin B ( conventional 0.7 mg/kg , i.v . daily ) plus 5-flucytosine ( 100 mg/kg orally daily , divide QID ) , Mycograb® . Study medication administer via central line peripheral venous line twice daily 7 consecutive day ( Days 1-7 ) . A lumbar puncture CSF culture colony count , India ink microscopy , measurement cryptococcal antigen ( CrAg ) perform Baseline , Days 3 , 7 , 14 , . CSF also assay concentration Mycograb® Days 3 , 7 , 14 . The primary efficacy parameter proportion subject consider cure day 14 ( combine clinical AND mycological outcome ) . A complimentary clinical trial run parallel study South America South Africa . The protocol use essentially describe except additional ( 3rd ) treatment arm ( Amphotericin B [ conventional 0.7 mg/kg , i.v . daily } Mycograb® ) .. An interim analysis perform 30 patient ( US and/or non-US ) complete Day 14 , follow reason : To evaluate safety Mycograb® review adverse event classify investigator possibly relate study drug To adjust propose sample size necessary . A Safety Monitoring Committee independent expert assess safety profile Mycograb® . A total 40 complete patient plan US . It estimate enrollment require 54 screen 48 enrol achieve 40 complete patient . The total duration trial approximately 24 month . If recruitment rate low US , number US may reduce , replace patient outside US cryptococcosis prevalent .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male nonpregnant female &gt; 18 year old , HIVpositive unknown , acute , either first recurrent episode cryptococcal meningitis Currently treatment , receive treatment ( &lt; 3 day ) either amphotericin B plus 5flucytosine , amphotericin B alone . Positive CSF culture Cryptococcus neoforman . Physical sign symptom meningitis , evidence one following : fever , headache , meningeal sign neurologic finding . Exclusion criterion : Excluded coma , significant medical condition . Subject opportunistic fungal infection require systemic antifungal therapy . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Cryptococcal meningitis</keyword>
</DOC>